Citations (119)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova & Tomas Dolezal. (2023) Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert Review of Gastroenterology & Hepatology 17:1, pages 99-108.
Read now
Read now
Akter Hossain, Mikael Lördal, Annika E. Olsson, Anette Storlåhls, Soo Aleman, Michael Eberhardson & Ragnar Befrits. (2020) Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 55:2, pages 178-183.
Read now
Read now
Belinda Jackson, Danny Con, Ronald Ma, Alexandra Gorelik, Danny Liew & Peter De Cruz. (2017) Health care costs associated with Australian tertiary inflammatory bowel disease care. Scandinavian Journal of Gastroenterology 52:8, pages 851-856.
Read now
Read now
Einar S. Björnsson & Anders Ekbom. (2015) Scandinavian epidemiological research in gastroenterology and hepatology. Scandinavian Journal of Gastroenterology 50:6, pages 636-648.
Read now
Read now
Paweł Kawalec & Krzysztof Piotr Malinowski. (2015) Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, pages 253-266.
Read now
Read now
Shmuel Odes & Dan Greenberg. (2014) A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. ClinicoEconomics and Outcomes Research 6, pages 431-443.
Read now
Read now
Chureen T Carter, Heidi C Waters & Daniel B Smith. (2012) Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease. Patient Preference and Adherence 6, pages 417-426.
Read now
Read now
Viviano Benedini, Nicola Caporaso, Gino Roberto Corazza, Zaccaria Rossi, Giovanni Fornaciari, Mario Cottone, Giorgio Frosini, Mauro Caruggi, Chiara Ottolini & Giorgio L Colombo. (2012) Burden of Crohn’s disease: economics and quality of life aspects in Italy. ClinicoEconomics and Outcomes Research 4, pages 209-218.
Read now
Read now
Sandro Ardizzone, Andrea Cassinotti & Roberto de Franchis. (2012) Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 17:4, pages 449-467.
Read now
Read now
Andrew Peng Yu, Louis A. Cabanilla, Eric Qiong Wu, Parvez M. Mulani & Jingdong Chao. (2008) The costs of Crohn's disease in the United States and other Western countries: a systematic review. Current Medical Research and Opinion 24:2, pages 319-328.
Read now
Read now
Tojo Thomas & Russell D Cohen. (2007) Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Review of Gastroenterology & Hepatology 1:1, pages 101-112.
Read now
Read now
Carlvin Luces & Keith Bodger. (2006) Economic burden of inflammatory bowel disease: a UK perspective. Expert Review of Pharmacoeconomics & Outcomes Research 6:4, pages 471-482.
Read now
Read now
M.-J. J. Mangen, A. H. Havelaar, R. A. J. A. M. Bernsen, R. Van Koningsveld & G. A. De Wit. (2005) The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. Acta Agriculturae Scandinavica, Section C — Food Economics 2:1, pages 35-51.
Read now
Read now
A. Eriksson, M. Shafazand, E. Jennische & S. Lange. (2003) Effect of antisecretory factor in ulcerative colitis on histological and laborative outcome: a short period clinical trial. Scandinavian Journal of Gastroenterology 38:10, pages 1045-1049.
Read now
Read now
Brian C McKaig & William A Stack. (1999) Current pharmacotherapy for inflammatory bowel disease. Expert Opinion on Pharmacotherapy 1:1, pages 3-14.
Read now
Read now
Articles from other publishers (104)
Majid Pakdin, Leila Zarei, Kamran Bagheri Lankarani & Sulmaz Ghahramani. (2023) The cost of illness analysis of inflammatory bowel disease. BMC Gastroenterology 23:1.
Crossref
Crossref
Rasmus Rankala, Juuso Kosonen, Kalle Mattila, Risto Tuominen, Markku Voutilainen & Anssi Mustonen. (2021) Direct costs of inflammatory bowel diseases in a Finnish tertiary-level clinic. Frontline Gastroenterology 12:5, pages 385-389.
Crossref
Crossref
Reinier Cornelis Anthonius van Linschoten, Elyke Visser, Christa Diana Niehot, C. Janneke van der Woude, Jan Antonius Hazelzet, Desirée van Noord & Rachel Louise West. (2021) Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Alimentary Pharmacology & Therapeutics 54:3, pages 234-248.
Crossref
Crossref
Berna Nilgün ÖZGÜRSOY URAN, Jülide Gülizar YILDIRIM, Elif SARITAŞ YÜKSEL, Funda SOFULU, Elif ÜNSAL AVDAL & Emine Özlem GÜR. (2021) Psychometric Characteristics of Turkish Adaptation of Inflammatory Bowel Diseases Fatigue Scale. Acibadem Universitesi Saglik Bilimleri Dergisi 12:2.
Crossref
Crossref
Berna ÖZGÜRSOY URAN, Elif SARITAŞ YÜKSEL, Elif ÜNSAL AVDAL & Burcu ARKAN. (2019) İnflamatuvar barsak hastalıklarında epidemiyolojik özellikler ve hastalık farkındağı; İzmir örneği ile kesitsel bir çalışma. Akademik Gastroenteroloji Dergisi 18:3, pages 112-119.
Crossref
Crossref
Catherine Le Berre, Laurent Peyrin-Biroulet, Anne Buisson, Alain Olympie, Marie-Hélène Ravel, Christina Bienenfeld & Florent Gonzalez. (2019) Impact of inflammatory bowel diseases on working life: A French nationwide survey. Digestive and Liver Disease 51:7, pages 961-966.
Crossref
Crossref
Wylezinski, Gray, Polk, Harmata & SpurlockIIIIII. (2019) Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. Journal of Clinical Medicine 8:4, pages 493.
Crossref
Crossref
M Ellen Kuenzig, Eric I Benchimol, Lawrence Lee, Laura E Targownik, Harminder Singh, Gilaad G Kaplan, Charles N Bernstein, Alain Bitton, Geoffrey C Nguyen, Kate Lee, Jane Cooke-Lauder & Sanjay K Murthy. (2019) The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology 2:Supplement_1, pages S17-S33.
Crossref
Crossref
M Ellen Kuenzig, Lawrence Lee, Wael El-Matary, Adam V Weizman, Eric I Benchimol, Gilaad G Kaplan, Geoffrey C Nguyen, Charles N Bernstein, Alain Bitton, Kate Lee, Jane Cooke-Lauder & Sanjay K Murthy. (2019) The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care. Journal of the Canadian Association of Gastroenterology 2:Supplement_1, pages S34-S41.
Crossref
Crossref
Sofie Coenen, Marie-Noëlle Schmickler, Daniëlle Staes, Frieda Wieme, Tony Swinnen, Xavier Dekeuleneer, Tineke van Hooland, Kris van den Cruys & Séverine Vermeire. (2019) Investing in workability of patients with inflammatory bowel disease: results of a pilot project Activ84worK (Activate for work). European Journal of Gastroenterology & Hepatology 31:1, pages 94-98.
Crossref
Crossref
F. J. Fernández-Pérez, A. M. Moreno-García, J. Hinojosa-Guadix & F. M. Vera-Rivero. (2018) Impacto del tratamiento biológico en la hospitalización y en el coste de la enfermedad inflamatoria intestinal. PharmacoEconomics Spanish Research Articles 14:3-4, pages 93-99.
Crossref
Crossref
Sonja Milovanovic, Franco Scaldaferri, Stefania Canarecci, Flavia Kheiraoui, Giulia Ciancarella, Chiara de Waure, Agnese Collamati, Elisa Schiavoni, Antonio Gasbarrini, Stefania Boccia & Andrea Poscia. (2017) Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease. Digestive and Liver Disease 49:10, pages 1098-1103.
Crossref
Crossref
Shala Ghaderi Berntsson, Anne-Marie Landtblom & Gullvi Flensner. (2017) Cerebellar ataxia and intrathecal baclofen therapy: Focus on patients´ experiences. PLOS ONE 12:6, pages e0180054.
Crossref
Crossref
Reena Khanna & Brian G. Feagan. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
291
297
.
Gilles Boschetti, Stephane Nancey, Fady Daniel, Benjamin Pariente, Eric Lerebours, Bernard Duclos, Arnaud Bourreille, Guillaume Cadiot, Mathurin Fumery, Jacques Moreau, Philippe Marteau, Yoram Bouhnik, Edouard Louis & Bernard Flourié. (2016) Costs of Crohnʼs Disease According to Severity States in France. Inflammatory Bowel Diseases 22:12, pages 2924-2932.
Crossref
Crossref
Marcin Włodarczyk, Aleksandra Sobolewska-Włodarczyk, Krystyna Stec-Michalska, Jakub Fichna & Maria Wiśniewska-Jarosińska. (2016) The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases. Pharmacological Reports 68:4, pages 852-858.
Crossref
Crossref
Mirthe E. van der Valk, Marie-Josée J. Mangen, Mirjam Severs, Mike van der Have, Gerard Dijkstra, Ad A. van Bodegraven, Herma H. Fidder, Dirk J. de Jong, C. Janneke van der Woude, Mariëlle J. L. Romberg-Camps, Cees H. M. Clemens, Jeroen M. Jansen, Paul C. van de Meeberg, Nofel Mahmmod, Andrea E. van der Meulen-de Jong, Cyriel Y. Ponsioen, Clemens Bolwerk, J. Reinoud Vermeijden, Peter D. Siersema, Max Leenders & Bas Oldenburg. (2016) Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. PLOS ONE 11:4, pages e0142481.
Crossref
Crossref
Mercedes Vergara, Beatriz Sicilia, Luis Prieto, Francesc Casellas, Alexis Ramos, Fernando Gomollón & Xavier Calvet. (2016) Development and Validation of the Short Crohnʼs Disease Work Disability Questionnaire. Inflammatory Bowel Diseases 22:4, pages 955-962.
Crossref
Crossref
J. E. Kreijne, M. R. K. L. Lie, L. Vogelaar & C. J. van der Woude. (2016) Practical Guideline for Fatigue Management in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 10:1, pages 105-111.
Crossref
Crossref
Xavier Aldeguer & Antoni Sicras-Mainar. (2016) Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study. Gastroenterología y Hepatología 39:1, pages 9-19.
Crossref
Crossref
Xavier Aldeguer & Antoni Sicras-Mainar. (2016) Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study. Gastroenterología y Hepatología (English Edition) 39:1, pages 9-19.
Crossref
Crossref
Giuseppe Lo Re, Dario Picone, Federica Vernuccio, Fabrizio Rabita, Gianfranco Cocorullo, Sergio Salerno, Massimo Galia & Massimo Midiri. 2016. Crohn’s Disease. Crohn’s Disease
137
146
.
Rupert W.L. Leong, Tony Huang, Yanna Ko, Ari Jeon, Jeff Chang, Friedbert Kohler & Viraj Kariyawasam. (2014) Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis. Journal of Crohn's and Colitis 8:10, pages 1237-1245.
Crossref
Crossref
Mike van der Have, Marie-Josée J. Mangen, Mirthe E. van der Valk, Hugo M. Smeets, Ad van Bodegraven, Gerard Dijkstra, Herma H. Fidder, Dirk J. de Jong, Marieke Pierik, Cyriel Y. Ponsioen, Andrea E. van der Meulen-de Jong, C. Janneke van der Woude, Paul C. van de Meeberg, Mariëlle J. L. Romberg-Camps, Cees H. M. Clemens, Jeroen M. Jansen, Nofel Mahmmod, Clemens J. M. Bolwerk, J. Reinoud Vermeijden, Peter D. Siersema, Max Leenders & Bas Oldenburg. (2014) Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 20:4, pages 637-645.
Crossref
Crossref
Edward V. LoftusJr.Jr.. 2014. GI Epidemiology. GI Epidemiology
273
284
.
Mirthe Emilie van der Valk, Marie-Josée J Mangen, Max Leenders, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, Marieke Pierik, C Janneke van der Woude, Mariëlle J L Romberg-Camps, Cees HM Clemens, Jeroen M Jansen, Nofel Mahmmod, Paul C van de Meeberg, Andrea E van der Meulen-de Jong, Cyriel Y Ponsioen, Clemens JM Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Martijn GH van Oijen & Bas Oldenburg. (2014) Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 63:1, pages 72-79.
Crossref
Crossref
M. Chaparro, C. Zanotti, P. Burgueño, I. Vera, F. Bermejo, I. Marín-Jiménez, C. Yela, P. López, M. D. Martín, C. Taxonera, B. Botella, R. Pajares, A. Ponferrada, M. Calvo, A. Algaba, L. Pérez, B. Casis, J. Maté, J. Orofino, N. Lara, M. García-Losa, X. Badia & J. P. Gisbert. (2013) Health Care Costs of Complex Perianal Fistula in Crohn’s Disease. Digestive Diseases and Sciences 58:12, pages 3400-3406.
Crossref
Crossref
Sunil Samuel, Steven B. Ingle, Shamina Dhillon, Siddhant Yadav, W. Scott Harmsen, Alan R. Zinsmeister, William J. Tremaine, William J. Sandborn & Edward V. LoftusJrJr. (2013) Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref
Martin Neovius, Elizabeth V. Arkema, Paul Blomqvist, Anders Ekbom & Karin E. Smedby. (2013) Patients With Ulcerative Colitis Miss More Days of Work Than the General Population, Even Following Colectomy. Gastroenterology 144:3, pages 536-543.
Crossref
Crossref
Edouard Louis, Robert Löfberg, Walter Reinisch, Anne Camez, Mei Yang, Paul F. Pollack, Naijun Chen, Jingdong Chao & Parvez M. Mulani. (2013) Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial. Journal of Crohn's and Colitis 7:1, pages 34-43.
Crossref
Crossref
Amosy E. M'koma. (2013) Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology 6, pages CGast.S12731.
Crossref
Crossref
Bincy P. Abraham & Joseph H. Sellin. (2012) Disability in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 41:2, pages 429-441.
Crossref
Crossref
C. Sack, V.A. Phan, R. Grafton, G. Holtmann, D.R. van Langenberg, K. Brett, M. Clark & J.M. Andrews. (2012) A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. Journal of Crohn's and Colitis 6:3, pages 302-310.
Crossref
Crossref
Konstantinos H. Katsanos, Athina Tatsioni, Natalia Pedersen, Mary Shuhaibar, Vicent Hernandez Ramirez, Patrizia Politi, Evelien Rombrechts, Marieke Pierik, Juan Clofent, Marina Beltrami, Paolo Bodini, Joao Freitas, Ioannis Mouzas, Giovanni Fornaciari, Bjorn Moum, Peter Laszlo Lakatos, Severine Vermeire, Ebbe Langholz, Selwyn Odes, Colm O'. Morain, Reinhold Stockbrügger, Pia Munkholm & Epameinondas V. Tsianos. (2011) Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study. Journal of Crohn's and Colitis 5:5, pages 430-442.
Crossref
Crossref
Antonio Di Sabatino, Lucio Liberato, Monia Marchetti, Paolo Biancheri & Gino R. Corazza. (2011) Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Internal and Emergency Medicine 6:S1, pages 17-27.
Crossref
Crossref
Henrik Stjernman, Curt Tysk, Sven Almer, Magnus Ström & Henrik Hjortswang. (2011) Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohnʼs disease. European Journal of Gastroenterology & Hepatology 23:8, pages 671-679.
Crossref
Crossref
Chureen T. Carter, Heidi C. Waters & Daniel B. Smith. (2011) Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Advances in Therapy 28:8, pages 671-683.
Crossref
Crossref
Keith Bodger. (2011) Cost Effectiveness of Treatments for Inflammatory Bowel Disease. PharmacoEconomics 29:5, pages 387-401.
Crossref
Crossref
B. G. Feagan, W. J. Sandborn, D. C. Wolf, G. Coteur, O. Purcaru, Y. Brabant & P. J. Rutgeerts. (2011) Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Alimentary Pharmacology & Therapeutics 33:5, pages 541-550.
Crossref
Crossref
Konstantinos H. Katsanos, Paraskevi Stamou, Athina Tatsioni, Vasileios E. Tsianos, Stefanos Zoumbas, Spyridoula Kavvadia, Anna Giga, Ioannis Vagias, Dimitrios K. Christodoulou & Epameinondas V. Tsianos. (2011) Prevalence of inflammatory bowel disease related dysplasia and cancer in 1500 colonoscopies from a referral center in northwestern Greece. Journal of Crohn's and Colitis 5:1, pages 19-23.
Crossref
Crossref
L.-P. Jelsness-Jørgensen, T. Bernklev, M. Henriksen, R. Torp & B. A. Moum. (2011) Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 33:1, pages 106-114.
Crossref
Crossref
Nanda Venu & Russell D. Cohen. 2011. Inflammatory Bowel Disease. Inflammatory Bowel Disease
295
313
.
Daniel R Van Langenberg, Kylie Lange, David J Hetzel, Gerald J Holtmann & Jane M Andrews. (2010) Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. Journal of Gastroenterology and Hepatology 25:7, pages 1250-1258.
Crossref
Crossref
T. V. Satyrova & E. I. Mikhailova. (2010) ULCERATIVE COLITIS: THE MODERN VIEW OF ETIOLOGY AND PATHOGENESIS (literature review). Health and Ecology Issues:2, pages 7-11.
Crossref
Crossref
B. G. FEAGAN, M. C. REILLY, L. GERLIER, Y. BRABANT, M. BROWN & S. SCHREIBER. (2010) Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate‐to‐severe Crohn’s disease in the PRECiSE 2 study. Alimentary Pharmacology & Therapeutics 31:12, pages 1276-1285.
Crossref
Crossref
R. D. COHEN, A. P. YU, E. Q. WU, J. XIE, P. M. MULANI & J. CHAO. (2010) Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmacology & Therapeutics 31:7, pages 693-707.
Crossref
Crossref
Yogesh Suresh Punekar, Thomas Sunderland, Neil Hawkins & James Lindsay. (2010) Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease. Value in Health 13:2, pages 188-195.
Crossref
Crossref
J. M. Andrews, R. E. Mountifield, D. R. Van Langenberg, P. A. Bampton & G. J. Holtmann. (2010) Un‐promoted issues in inflammatory bowel disease: opportunities to optimize care. Internal Medicine Journal 40:3, pages 173-182.
Crossref
Crossref
Russell D. Cohen. (2010) The pharmacoeconomics of biologic therapy for IBD. Nature Reviews Gastroenterology & Hepatology 7:2, pages 103-109.
Crossref
Crossref
Bruce E. Sands & Corey A. Siegel. 2010. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease
1941
1973.e9
.
Marco Scarpa, Cesare Ruffolo, Domenico Bassi, Riccardo Boetto, Renata D’Incà, Andrea Buda, Giacomo C. Sturniolo & Imerio Angriman. (2009) Intestinal Surgery for Crohn’s Disease: Predictors of Recovery, Quality of Life, and Costs. Journal of Gastrointestinal Surgery 13:12, pages 2128-2135.
Crossref
Crossref
Johan Mesterton, Linus Jönsson, Sven H.C. Almer, Ragnar Befrits, Ingalill Friis-Liby & Stefan Lindgren. (2009) Resource use and societal costs for Crohnʼs disease in Sweden. Inflammatory Bowel Diseases 15:12, pages 1882-1890.
Crossref
Crossref
Carlos Taxonera, Luis Rodrigo, Francesc Casellas, Xavier Calvet, Federico Gómez-Camacho, Daniel Ginard, Manuel Castro, Luisa Castro, Marta Ponce, Pilar Martínez-Montiel, Elena Ricart, Javier P. Gisbert, Antonio López-San Román, José M. Morales & Miguel Á. Casado. (2009) Infliximab Maintenance Therapy Is Associated With Decreases in Direct Resource Use in Patients With Luminal or Fistulizing Crohn's Disease. Journal of Clinical Gastroenterology 43:10, pages 950-956.
Crossref
Crossref
William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands & Jean Frédéric Colombel. (2009) Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology 137:4, pages 1250-1260.
Crossref
Crossref
Geoffrey C. Nguyen, Justina Sam, Sanjay K. Murthy, Gilaad G. Kaplan, Jill M. Tinmouth & Thomas A. LaVeist. (2009) Hospitalizations for inflammatory bowel disease: Profile of the uninsured in the United States. Inflammatory Bowel Diseases 15:5, pages 726-733.
Crossref
Crossref
Amosy E. M'Koma, Paul E. Wise, David A. Schwartz, Roberta L. Muldoon & Alan J. Herline. (2009) Prevalence and Outcome of Anemia After Restorative Proctocolectomy. Diseases of the Colon & Rectum 52:4, pages 726-739.
Crossref
Crossref
Edward V. LoftusJr.Jr., Howard S. Friedman, David J. Delgado & William J. Sandborn. (2009) Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflammatory Bowel Diseases 15:4, pages 566-575.
Crossref
Crossref
William N. Tindall. (2009) New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. American Journal of Health-System Pharmacy 66:5, pages 451-457.
Crossref
Crossref
Athanasios G. Pallis, Petros A. Kostagiolas, Ioannis A. Mouzas & Dimitris Niakas. (2009) Patients’ perceptions as an indicator of quality of care, in Greek patients with inflammatory bowel disease. Scandinavian Journal of Caring Sciences 23:1, pages 93-99.
Crossref
Crossref
Geoffrey C. Nguyen & Hillary A. Steinhart. (2008) Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflammatory Bowel Diseases 14:12, pages 1688-1694.
Crossref
Crossref
Teresa B. Gibson, Eliza Ng, Ronald J. Ozminkowski, Shaohung Wang, Wayne N. Burton, Ron Z. Goetzel & Ross Maclean. (2008) The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis. Journal of Occupational & Environmental Medicine 50:11, pages 1261-1272.
Crossref
Crossref
A. Timmer. (2008) How often and for how long are IBD patients expected to be sick, off work, or in hospital each year?. Inflammatory Bowel Diseases 14:Supplement, pages S48-S49.
Crossref
Crossref
A. Timmer. (2008) How often and for how long are IBD patients expected to be sick, off work, or in hospital each year?. Inflammatory Bowel Diseases 14, pages S48-S49.
Crossref
Crossref
J. LINDSAY, Y. S. PUNEKAR, J. MORRIS & G. CHUNG-FAYE. (2008) Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology & Therapeutics 28:1, pages 76-87.
Crossref
Crossref
Margarita Elkjaer, Gabrielle Moser, Walter Reinisch, Dana Durovicova, Milan Lukas, Boris Vucelic, Vibeke Wewer, Jean Frederic Colombel, Mary Shuhaibar, Colm O'Morain, Patrizia Politi, Selwyn Odes, Tomm Bernklev, Tom Øresland, Inna Nikulina, Elena Belousova, Ingrid Van der Eijk & Pia Munkholm. (2008) IBD patients need in health quality of care ECCO consensus. Journal of Crohn's and Colitis 2:2, pages 181-188.
Crossref
Crossref
Selwyn Odes. (2008) How expensive is inflammatory bowel disease? A critical analysis. World Journal of Gastroenterology 14:43, pages 6641.
Crossref
Crossref
I. Blumenstein, H. Bock, C. Weber, A. Rambow, W. Tacke, R. Kihn, R. Pfaff, S. Orlemann, R. Schaeffer, O. Schröder, A. Digna, F. Hartmann & J. Stein. (2008) Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: A multicenter, prospective, internet-based study. Inflammatory Bowel Diseases 14:1, pages 53-60.
Crossref
Crossref
C. SARO, C. DE LA COBA, M. Á. CASADO, J. M. MORALES & B. OTERO. (2007) Resource use in patients with Crohn’s disease treated with infliximab. Alimentary Pharmacology & Therapeutics 26:10, pages 1313-1323.
Crossref
Crossref
Peter R Gibson, Adèle R Weston, Amelia Shann, Timothy H J Florin, Ian C Lawrance, Finlay A Macrae & Graham Radford-Smith. (2007) Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. Journal of Gastroenterology and Hepatology 22:8, pages 1306-1312.
Crossref
Crossref
J. Panés, M. Guilera, D. Ginard, J. Hinojosa, P. González-Carro, V. González-Lara, V. Varea, E. Domènech & X. Badia. (2007) Treatment cost of ulcerative colitis. Digestive and Liver Disease 39:7, pages 617-625.
Crossref
Crossref
Timothy L. Zisman & Russell D. Cohen. (2007) Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Current Treatment Options in Gastroenterology 10:3, pages 185-194.
Crossref
Crossref
Edward V. LoftusJrJr. 2007. GI Epidemiology. GI Epidemiology
198
206
.
Martin Rejler, Anna Spångéus, Jörgen Tholstrup & Boel Andersson-Gäre. (2007) Improved Population-based Care. Quality Management in Health Care 16:1, pages 38-50.
Crossref
Crossref
Russell D. Cohen & Tojo Thomas. (2006) Economics of the Use of Biologics in the Treatment of Inflammatory Bowel Disease. Gastroenterology Clinics of North America 35:4, pages 867-882.
Crossref
Crossref
Selwyn Odes, Hillel Vardi, Michael Friger, Frank Wolters, Maurice G. Russel, Lene Riis, Pia Munkholm, Patrizia Politi, Epameinondas Tsianos, Juan Clofent, Severine Vermeire, Estela Monteiro, Iannis Mouzas, Giovanni Fornaciari, Jildou Sijbrandij, Charles Limonard, Gilbert Van Zeijl, Colm O’Morain, Bjørn Moum, Morten Vatn & Reinhold Stockbrugger. (2006) Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation. Gastroenterology 131:3, pages 719-728.
Crossref
Crossref
Teresa Longobardi & Charles N. Bernstein. (2006) Health Care Resource Utilization in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 4:6, pages 731-743.
Crossref
Crossref
S. V. KANE. (2006) Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 23:5, pages 577-585.
Crossref
Crossref
Y Leung. (2006) Hematopoietic cell transplantation for Crohn’s disease; is it time?. World Journal of Gastroenterology 12:41, pages 6665.
Crossref
Crossref
Renee Stark, Hans-Helmut K??nig & Reiner Leidl. (2006) Costs of Inflammatory Bowel Disease in Germany. PharmacoEconomics 24:8, pages 797-814.
Crossref
Crossref
Brian G Feagan, Mohan Bala, Songkai Yan, Allan Olson & Stephen Hanauer. (2005) Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease. Journal of Clinical Gastroenterology 39:5, pages 390-395.
Crossref
Crossref
Sheetal R. Marri & Alan L. Buchman. (2005) The Education and Employment Status of Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 11:2, pages 171-177.
Crossref
Crossref
Ingrid van der Eijk, Ioannis G. Vlachonikolis, Pia Munkholm, Judy Nijman, Tomm Bernklev, Patrizia Politi, Selwyn Odes, Epameinondas V. Tsianos, Reinhold W. Stockbrügger & Maurice G. Russel. (2004) The Role of Quality of Care in Health-related Quality of Life in Patients with IBD. Inflammatory Bowel Diseases 10:4, pages 392-398.
Crossref
Crossref
Paul Rutgeerts, Gert van Assche & Séverine Vermeire. (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:6, pages 1593-1610.
Crossref
Crossref
MARGRIT EBINGER, REINER LEIDL, Stefanie Thomas, Christian Von Tirpitz, MAX REINSHAGEN, GUIDO ADLER & HANS-HELMUT KONIG. (2004) Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. Journal of Gastroenterology and Hepatology 19:2, pages 192-199.
Crossref
Crossref
Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein, Lloyd F. Mayer, Stefan Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Weihang Bao & Stephen B. Hanauer. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:2, pages 402-413.
Crossref
Crossref
M. Soncini, O. Triossi, P. Leo & G. Magni. (2004) Inflammatory bowel disease and hospital treatment in Italy: the RING multi-centre study. Alimentary Pharmacology & Therapeutics 19:1, pages 63-68.
Crossref
Crossref
J Juan, R Estiarte, E Colomé, M Artés, F.J Jiménez & J Alonso. (2003) Burden of illness of Crohn’s disease in Spain. Digestive and Liver Disease 35:12, pages 853-861.
Crossref
Crossref
Teresa Longobardi, Philip Jacobs & Charles N Bernstein. (2003) Work Losses Related To Inflammatory Bowel Disease in The United States: Results From The National Health Interview Survey. American Journal of Gastroenterology 98:5, pages 1064-1072.
Crossref
Crossref
Charles O. Elson, R. Balfour Sartor, Stephan R. Targan & William J. Sandborn. (2003) Challenges in IBD Research: Updating the Scientific Agendas. Inflammatory Bowel Diseases 9:3, pages 137-153.
Crossref
Crossref
Russell D. Cohen. (2003) IBD: the drugs work...but do the patients?. The American Journal of Gastroenterology 98:4, pages 722-723.
Crossref
Crossref
Teresa Longobardi, Philip Jacobs, Lieling Wu & Charles N. Bernstein. (2003) Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. The American Journal of Gastroenterology 98:4, pages 844-849.
Crossref
Crossref
Brian G. Feagan. 2003. Inflammatory Bowel Disease: From Bench to Bedside. Inflammatory Bowel Disease: From Bench to Bedside
471
480
.
Annelies Boonen, Pieter C. Dagnelie, Anita Feleus, Martine A. Hesselink, Jean W. Muris, Reinhold W. Stockbrügger & Maurice G. Russel. (2002) The Impact of Inflammatory Bowel Disease on Labor Force Participation: Results of a Population Sampled Case-Control Study. Inflammatory Bowel Diseases 8:6, pages 382-389.
Crossref
Crossref
Joel H. Rubenstein, Rachel Y. Chong & Russell D. Cohen. (2002) Infliximab Decreases Resource Use Among Patients With Crohn's Disease. Journal of Clinical Gastroenterology 35:2, pages 151-156.
Crossref
Crossref
Keith Bodger. (2002) Cost of Illness of Crohn??s Disease. PharmacoEconomics 20:10, pages 639-652.
Crossref
Crossref
Ingrid Eijk, Herman Sixma, Tamara Smeets, Fernando Tavarela Veloso, Selwyn Odes, Sean Montague, Giovanni Fornaciari, Bjorn Moum, Reinhold StockbruggerStockbrugger & Maurice Russel. (2001) Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results. The American Journal of Gastroenterology 96:12, pages 3329-3336.
Crossref
Crossref
P. Blomqvist, N. Feltelius, R. Löfberg & A. Ekbom. (2003) A 10‐year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions. Alimentary Pharmacology & Therapeutics 15:4, pages 475-481.
Crossref
Crossref
Russell D. Cohen. (2000) The Cost of Crohn??s Disease. BioDrugs 14:5, pages 331-344.
Crossref
Crossref
Ingrid van der Eijk, Reinhold Stockbrügger & Maurice Russel. (2000) Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. European Journal of Internal Medicine 11:4, pages 228-234.
Crossref
Crossref
William J. Sandborn. (2000) Therapy for Crohn disease. Current Opinion in Gastroenterology 16:4, pages 318-323.
Crossref
Crossref
Charles N. Bernstein, Noreen Papineau, Janelle Zajaczkowski, Patricia Rawsthorne, Gisele Okrusko & James F. Blanchard. (2000) Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital. The American Journal of Gastroenterology 95:3, pages 677-683.
Crossref
Crossref
Russell D Cohen, Leanne R Larson, Joel M Roth, Russell V Becker & Lisa L Mummert. (2000) The Cost of Hospitalization in Crohn's Disease. American Journal of Gastroenterology 95:2, pages 524-530.
Crossref
Crossref
B.G. Feagan. (1999) Review article: economic issues in Crohn’s disease - assessing the effects of new treatments on health-related quality of life. Alimentary Pharmacology & Therapeutics 13, pages 29-37.
Crossref
Crossref
Marc D. Silverstein, Edward V. LoftusJr.Jr., William J. Sandborn, William J. Tremaine, Brian G. Feagan, Paul J. Nietert, W.Scott Harmsen & Alan R. Zinsmeister. (1999) Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117:1, pages 49-57.
Crossref
Crossref